Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms inhalation powder
Sponsors
Areteia Therapeutics Inc.
Conditions
Severe eosinophilic asthma
Phase 3
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
WithdrawnCTIS2023-503693-20-00
Target: 20Updated: 2023-09-12
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
CompletedCTIS2023-503693-20-01
Start: 2024-04-10End: 2025-11-05Target: 490Updated: 2025-12-16